Cardiovascular Therapeutics 2008-01-01

Role of adenosine antagonism in the cardiorenal syndrome.

Mustafa M Dohadwala, Michael M Givertz

Index: Cardiovasc. Ther. 26(4) , 276-86, (2008)

Full Text: HTML

Abstract

Acute decompensated heart failure (ADHF), generally related to signs and symptoms of volume overload, is one the most common reasons for hospitalization in the United States. Recently, it has been observed that the majority of patients with ADHF have baseline renal dysfunction. Moreover, heart failure (HF) treatment is limited by worsening renal function despite persistent volume overload. This connection between HF and renal dysfunction has been termed the cardiorenal syndrome and has made treatment of patients with stable and unstable HF challenging. Selective adenosine A1 receptor antagonists are novel pharmacologic agents that are currently under development to treat volume overload in HF while protecting or possibly improving renal function. In this article, we review the cardiorenal syndrome, the role of adenosine in renal function, and emerging data regarding the safety and efficacy of adenosine A1 receptor antagonists in patients with advanced HF.

Related Compounds

  • KW 3902

Related Articles:

The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.

2010-01-01

[Am. J. Ther. 17(1) , 53-60, (2010)]

The disconnect between phase II and phase III trials of drugs for heart failure.

2013-02-01

[Nat. Rev. Cardiol. 10(2) , 85-97, (2013)]

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.

2010-01-01

[J. Card. Fail. 16(1) , 25-35, (2010)]

Adenosine A2 receptor activation attenuates afferent arteriolar autoregulation during adenosine receptor saturation in rats.

2007-10-01

[Hypertension 50(4) , 744-9, (2007)]

Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.

2010-11-01

[Eur. J. Heart Fail. 12(11) , 1238-46, (2010)]

More Articles...